• BIA Blog

CEO Update | Monday 10 December 2018

Expect ongoing Westminster drama on Brexit this week. We’ll monitor and respond appropriately on behalf of our members and then provide a Christmas wrapped analysis of what it all means for our sector on Wednesday 17th December at our final webinar of the year.

Impact of ELIXIR infrastructure

ELIXIR is an intergovernmental organisation that unites leading life science organisations in managing and safeguarding the increasing volume of data being generated. ELIXIR coordinates, integrates and sustains bioinformatics resources and services across its Nodes, and enables users in academia and industry to freely access services that are vital for their work.

Connecting the holy trinity: life science sector, academia and NHS data

Last week, Health Data Research UK (HDR UK) organised an industry workshop, with support from the BIA, to discuss the implementation of the Digital Innovation Hubs. The Hubs were first recommended in the Life Sciences Industrial Strategy and last week’s event marked a (small) step forward in making them a reality.

CEO Update | Monday 3 December

Today the government announced funding for a new Vaccines Manufacturing Innovation Centre to be built in Oxford. Led by the Jenner Institute, a partnership between the University of Oxford and the Pirbright Institute, the new centre has been awarded funding by UK Research and Innovation of £66 million through the UK government’s Industrial Strategy Challenge Fund (ISCF) Medicines Manufacturing challenge. Additional funding of £10 million will come from commercial and other partners, including Janssen Vaccines & Prevention B.V. and Merck Sharp and Dohme. The centre will be further supported by expertise and training from GE Healthcare. The core research teams will be drawn from academia and industry and will include significant new contributions from the London School of Hygiene & Tropical

Video of the week | Yarvie | Raising Money

The Scientific Founders behind some of the UK's most exciting emerging biotech companies share their perspective on building a business around their science.

BIA City and Finance Update November 2018

Deals remain the key driver of interest for the life sciences financial sector with a successful Jefferies Conference.  Also this month, BTG plc was sold to Boston Scientific for £3.3bn, which looks set to boost cash inflows for investors in H1 2019. Also, in this edition, the Efficient Market Hypothesis – and we meet Bioscience Managers.

CEO Update | Monday 26 November

With a Brexit deal signed between the EU and the UK at the weekend, we’ll be distributing our Brexit briefing on what it means for our sector to members tomorrow. We’ll follow that with our monthly Brexit webinar this Friday where myself and Laura Collister will put the deal in its political context, analyse the next stage of parliamentary ratification and endeavour to answer your questions. 

Gene editing in Parliament

This week, the BIA together with our colleagues at the ABPI and BIVDA relaunched the All Party-Parliamentary Group (APPG) for Life Sciences. The APPG is a cross-party group for MPs and Peers with an interest in the sector and is chaired by Daniel Zeichner MP (Lab) and vice-chaired by Chris Green MP (Con). The APPG will work to raise awareness and understanding in Parliament of the valuable contribution the life sciences sector provides to the health and wealth of the nation.

CEO Update Monday 19 November 2018

Brexit continues to dominate the headlines and last week we welcomed the progress on Brexit discussions as we saw initial agreement between the EU and UK on a withdrawal agreement and the political agreement on the outline of a future relationship.

Event Feature: Window on Wuhan